Interest of the Donor-specific Antibodies After Liver Transplantation

Interest of the Donor-specific and Complement-binding Anti-HLA Antibodies (C1q) Assays for the Management and the Monitoring After Liver Transplant

The study is a prospective observational mono center study

Primary objective :

Study the anti-HLA antibodies frequency preformed before liver transplantation and the kinetic of appearance of DSA and de novo complement-binding anti-HLA antibodies after liver transplantation.

Secondary objective :

• Risk factor of de novo DSA appearance (Immunosuppressive therapy, liver aetiology)

• Impact of DSA on:

  • Graft and patients survivals
  • Onset of allograft rejection (acute, late-onset, chronic)
  • Unexplained liver graft dysfunction
  • Unexplained liver enzymes abnormalities
  • Liver fibrosis development (liver stiffness study using fibroscan©)

Inclusion Criteria:

• Liver transplanted patients older than 18, transplanted in Lille University Hospital.
• Written consent by the patient or his/her legal representative (especially patient with hepatic encephalopathy).
• Patients with health insurance

Exclusion Criteria:

• Minor patients.
• Pregnant women or during lactation.
• Patient under curatorship.